These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 30704255)

  • 1. [PCSK9 inhibitors and diabetes mellitus].
    Vohnout B; Lisičanová J; Havranová A
    Vnitr Lek; 2019; 64(12):1186-1189. PubMed ID: 30704255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of proprotein convertase subtilisin/kexin 9 inhibitors in people with diabetes and dyslipidaemia.
    Dijk W; Cariou B
    Diabetes Obes Metab; 2019 Apr; 21 Suppl 1():39-51. PubMed ID: 31002456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of PCSK9 Monoclonal Antibodies in Patients With Diabetes.
    Marouf BH; Iqbal Z; Mohamad JB; Bashir B; Schofield J; Syed A; Kilpatrick ES; Stefanutti C; Soran H
    Clin Ther; 2022 Feb; 44(2):331-348. PubMed ID: 35246337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9.
    Jang HD; Lee SE; Yang J; Lee HC; Shin D; Lee H; Lee J; Jin S; Kim S; Lee SJ; You J; Park HW; Nam KY; Lee SH; Park SW; Kim JS; Kim SY; Kwon YW; Kwak SH; Yang HM; Kim HS
    Eur Heart J; 2020 Jan; 41(2):239-252. PubMed ID: 31419281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation.
    Weider E; Susan-Resiga D; Essalmani R; Hamelin J; Asselin MC; Nimesh S; Ashraf Y; Wycoff KL; Zhang J; Prat A; Seidah NG
    J Biol Chem; 2016 Aug; 291(32):16659-71. PubMed ID: 27284008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic Assessment of Potential Long-Term On-Target Side Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors.
    Nelson CP; Lai FY; Nath M; Ye S; Webb TR; Schunkert H; Samani NJ
    Circ Genom Precis Med; 2019 Jan; 12(1):e002196. PubMed ID: 30645167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low-density lipoprotein receptor.
    Da Dalt L; Ruscica M; Bonacina F; Balzarotti G; Dhyani A; Di Cairano E; Baragetti A; Arnaboldi L; De Metrio S; Pellegatta F; Grigore L; Botta M; Macchi C; Uboldi P; Perego C; Catapano AL; Norata GD
    Eur Heart J; 2019 Jan; 40(4):357-368. PubMed ID: 29982592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE.
    Ason B; van der Hoorn JW; Chan J; Lee E; Pieterman EJ; Nguyen KK; Di M; Shetterly S; Tang J; Yeh WC; Schwarz M; Jukema JW; Scott R; Wasserman SM; Princen HM; Jackson S
    J Lipid Res; 2014 Nov; 55(11):2370-9. PubMed ID: 25258384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies on new-onset diabetes mellitus and glucose metabolism: A systematic review and meta-analysis.
    Cao YX; Liu HH; Dong QT; Li S; Li JJ
    Diabetes Obes Metab; 2018 Jun; 20(6):1391-1398. PubMed ID: 29377473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies.
    Seidah NG; Prat A; Pirillo A; Catapano AL; Norata GD
    Cardiovasc Res; 2019 Mar; 115(3):510-518. PubMed ID: 30629143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid Lowering Therapy and Circulating PCSK9 Concentration.
    Nozue T
    J Atheroscler Thromb; 2017 Sep; 24(9):895-907. PubMed ID: 28804094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ascorbic acid enhances low-density lipoprotein receptor expression by suppressing proprotein convertase subtilisin/kexin 9 expression.
    Wang D; Yang X; Chen Y; Gong K; Yu M; Gao Y; Wu X; Hu H; Liao C; Han J; Duan Y
    J Biol Chem; 2020 Nov; 295(47):15870-15882. PubMed ID: 32913121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Effect of Proprotein Convertase Subtilisin-Kexin Type 9 and its Inhibition on Glucose Metabolism and Cardiovascular Risk. We Should do Better the Second Time After Statins.
    Athyros VG; Tziomalos K; Doumas M; Sfikas G; Karagiannis A
    Curr Pharm Des; 2017; 23(10):1477-1483. PubMed ID: 28128061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential Effects of DPP-4 Inhibitors, Anagliptin and Sitagliptin, on PCSK9 Levels in Patients with Type 2 Diabetes Mellitus who are Receiving Statin Therapy.
    Furuhashi M; Sakuma I; Morimoto T; Higashiura Y; Sakai A; Matsumoto M; Sakuma M; Shimabukuro M; Nomiyama T; Arasaki O; Node K; Ueda S
    J Atheroscler Thromb; 2022 Jan; 29(1):24-37. PubMed ID: 33342939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating Rather Than Intestinal PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Regulates Postprandial Lipemia in Mice.
    Garçon D; Moreau F; Ayer A; Dijk W; Prieur X; Arnaud L; Roubtsova A; Seidah N; Prat A; Cariou B; Le May C
    Arterioscler Thromb Vasc Biol; 2020 Sep; 40(9):2084-2094. PubMed ID: 32673528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proprotein Convertase Subtilisin/Kexin-Type 9 and Lipid Metabolism.
    Guo S; Xia XD; Gu HM; Zhang DW
    Adv Exp Med Biol; 2020; 1276():137-156. PubMed ID: 32705598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction.
    Tavori H; Melone M; Rashid S
    Expert Rev Cardiovasc Ther; 2014 Oct; 12(10):1137-44. PubMed ID: 25244623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.
    Bergeron N; Phan BA; Ding Y; Fong A; Krauss RM
    Circulation; 2015 Oct; 132(17):1648-66. PubMed ID: 26503748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.